KYPROLIS

This brand name is authorized in Austria, Australia, Brazil, Canada, Cyprus, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Italy, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, Turkey, United Kingdom, United States

Active ingredients

The drug KYPROLIS contains one active pharmaceutical ingredient (API):

1 Carfilzomib UNII 72X6E3J5AR - CARFILZOMIB

Carfilzomib is a tetrapeptide epoxyketone proteasome inhibitor that selectively and irreversibly binds to the N-terminal threonine containing active sites of the 20S proteasome, the proteolytic core particle within the 26S proteasome, and displays little to no activity against other protease classes. Carfilzomib had antiproliferative and proapoptotic activities in preclinical models in haematologic tumours. Read about Carfilzomib

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
KYPROLIS Powder for solution for infusion	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01XG02		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XG Proteasome inhibitors
Discover more medicines within L01XG02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 11229B, 11230C, 12243J, 12244K
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 544116100003701
Country: CA	Health Products and Food Branch	Identifier(s): 02451034, 02459930, 02459949
Country: EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	Identifier(s): 4764-MEE-0719
Country: EE	Ravimiamet	Identifier(s): 1703911, 1735680, 1735691
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 1151060001, 1151060002, 1151060003, 115106001IP
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 090435, 534401, 542915
Country: FR	Base de données publique des médicaments	Identifier(s): 62529551, 64296925, 69270884
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 311435, 345309, 345315, 392404
Country: HK	Department of Health Drug Office	Identifier(s): 64828, 65431
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 7400
Country: IT	Agenzia del Farmaco	Identifier(s): 044553016, 044553028, 044553030
Country: JP	医薬品医療機器総合機構	Identifier(s): 4291433D1026, 4291433D2022
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1079120, 1082362, 1082363
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 129399, 134902, 134910
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 19151, 19212
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100359181, 100378132, 100378149
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W62506001
Country: SG	Health Sciences Authority	Identifier(s): 15184P, 15414P
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8699862270014
Country: US	FDA, National Drug Code	Identifier(s): 76075-101, 76075-102, 76075-103